Latest Breaking News On - Safety review committees - Page 1 : comparemela.com

Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target .

United statesPankaj mohanJack yauchRobert wenhamRichard kenneySonnet biotherapeutics holdings incExchange commissionSolebury strategic communicationsOncology at moffitt cancer centerCompany or sonnetRoche groupSecurities exchangeFully human albumin bindingSecreted protein acidicSafety review committeesChief medical

Sonnet BioTherapeutics, Inc : Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10

United statesPankaj mohanJack yauchRobert wenhamRichard kenneySonnet biotherapeutics holdings incSolebury strategic communicationsExchange commissionOncology at moffitt cancer centerCompany or sonnetRoche groupSecurities exchangeFully human albumin bindingSecreted protein acidicSafety review committeesChief medical

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

Robert wenhamRichard kenneyNews networkSonnet biotherapeutics holdings incRoche groupOncology at moffitt cancer centerCompany or sonnetFully human albumin bindingSecreted protein acidicSafety review committeesChief medicalResponse evaluation criteriaSolid tumorsMoffitt cancer centerLead principal investigator

Sonnet BioTherapeutics (SONN) Reports Updated Clinical Data for SON-1010

Sonnet BioTherapeutics (SONN) Reports Updated Clinical Data for SON-1010
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Robert wenhamRichard kenneyPankaj mohanOncology at moffitt cancer centerSonnet biotherapeutics holdings incRoche groupFully human albumin bindingSecreted protein acidicSafety review committeesChief medicalResponse evaluation criteriaSolid tumorsMoffitt cancer centerLead principal investigatorSonnet founderChief executive

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

United statesPankaj mohanJack yauchRobert wenhamRichard kenneySecurities exchangeOncology at moffitt cancer centerSolebury strategic communicationsRoche groupCompany or sonnetExchange commissionSonnet biotherapeutics holdings incFully human albumin bindingSecreted protein acidicSafety review committeesChief medical